Galaxy Therapeutics Achieves CE Mark for SEAL™ Embolization System, Enabling Commercial Launch Across Europe and International Markets
MILPITAS, Calif., Aug. 4, 2026 /PRNewswire/ -- Galaxy Therapeutics, a privately held medical device company dedicated to advancing the treatment of intracranial aneurysms, today announced that it has received CE Mark under the European Medical Device Regulation (EU MDR 2017/745) for the...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.